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item questionnaire. Although the two new versions of the IPSO
shared only 6 items, both reﬂected the original IPSO well.
However, several arguments such as lower correlation coefﬁ-
cients, higher Chronbach’s alpha’s, ordered thresholds, unidi-
mensionality and less differences among subgroups of patients
suggested that the Rasch version of the IPSO may be the pre-
ferred instrument to use. CONCLUSION: The IPSO can be
improved and shortened and the Rash reduced version of this
instrument is likely to assess the psychosocial impact of moder-
ate to severe psoriasis on patients’ lives best because it is a short,
reliable and unidimensional measurement.
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OBJECTIVES: Because of physical limitations associated with
psoriasis, dermatologic-related functional ability can be an
important endpoint to assess effectiveness of treatment. This
study was performed to assess the correlation between clinical
efﬁcacy and improvement in functional ability in moderate to
severe plaque psoriasis patients treated with adalimumab for 12
weeks. METHODS: In a randomized, double-blind, placebo-
controlled, multi-center clinical trial for the treatment of mod-
erate to severe plaque psoriasis with adalimumab, the correlation
between clinical efﬁcacy and change in dermatology-speciﬁc
functional limitations was evaluated. Clinical efﬁcacy was
assessed using the Psoriasis Area and Severity Index (PASI) and
the Physician’s Global Assessment (PGA) of Disease Severity. The
Dermatology Life Quality Index (DLQI) was used to measure
dermatologic-speciﬁc functional limitations. Mean changes in
DLQI scores were evaluated for patient responses between base-
line and 12 weeks. RESULTS: The DLQI was shown to have
good reliability, and to demonstrate responsiveness to change
with the subjects’ PASI and PGA scores from baseline to week
12. The correlation between DLQI and PASI response was 0.69
(p < 0.001), and between DLQI and PGA response was 0.71 (p
< 0.001). Mean change in DLQI was +12.17 points in patients
who achieved signiﬁcant clinical beneﬁt (> = PASI 75 response)
vs. +1.77 points in nonresponders (less than PASI 50 response).
CONCLUSIONS: DLQI was demonstrated to be highly respon-
sive to clinical changes in patients with moderate to severe
plaque psoriasis. The level of agreement suggests that adali-
mumab may be highly effective in improving both the physical
disease manifestations and functional ability of patients with
moderate to severe plaque psoriasis.
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OBJECTIVES: Because moderate to severe psoriasis can nega-
tively impact patients’ daily living, quality of life can be an
important parameter to assess in determining effectiveness of
treatment. This study was performed to assess the correlation
between clinical efﬁcacy and quality-of-life improvement in mod-
erate to severe plaque psoriasis patients treated with adalimumab
for 12 weeks. METHODS: In a randomized, double-blind,
placebo-controlled, multi-center clinical trial for the treatment of
moderate to severe plaque psoriasis with adalimumab, the cor-
relation between clinical efﬁcacy and quality of life was evalu-
ated. Clinical efﬁcacy was assessed using the Psoriasis Area and
Severity Index (PASI) and the Physician Global Assessment
(PGA) of disease severity. Euro-QOL 5D (EQ-5D) visual ana-
logue score was used to assess general quality of life. Mean
changes in EQ-5D scores were evaluated for patient responses
between baseline and 12 weeks. RESULTS: EQ-5D demon-
strated responsiveness to changes in clinical efﬁcacy. The corre-
lation between EQ-5D and PASI response was 0.57 (p < 0.001),
and between EQ-5D and PGA response was 0.44 (p < 0.001).
Mean change in EQ-5D was 15.69 points in patients who had
achieved signiﬁcant clinical beneﬁt (>PASI 75 response) vs. 1.92
points in non-responders (<PASI 50 response). CONCLUSION:
EQ-5D was demonstrated to be responsive to clinical changes in
patients with moderate to severe plaque psoriasis. The level of
agreement suggests that adalimumab may be highly effective in
improving both the physical disease manifestations and quality
of life of patients with moderate to severe plaque psoriasis.
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OBJECTIVES: The aim was to evaluate the consequences of pso-
riasis on quality of life and pay particular attention to those with
nail psoriasis. METHODS: In October 2004, a questionnaire
was sent to 4000 members, selected by drawing lots, among the
French patients support group (APLCP). The ﬁrst part concerned
the social and demographic characteristics of the patients, pso-
riasis localization and psoriasis age. The second part was dedi-
cated to patients with nail psoriasis. The last part was the
Dermatology Life Quality Index (DLQI) which was ﬁlled in by
all patients. RESULTS: A total of 1309 questionnaires were
returned with 57.3% of women and 42.7% of men. Mean age
was 51.8 years (SD = 16.2). Psoriasis affected the nails for 60.8%
of subjects (16.4% for the hands only, 9.4% for the feet only
and 35% for both the hands and feet). The DLQI score was
available for 1111 individuals with an average score of 8.3 (SD
= 6.5). It was signiﬁcantly related to gender with a score of 7.6
(SD = 6.2) for men and 9 (SD = 6.8) for women (p = 0.0333). It
was also signiﬁcantly related to age, the younger the individuals,
the more quality of life was affected: 9.4 (SD = 6.6) for the group
“39 years old and under”, 9.2 (SD = 6.7) for the group “40–54
years”, 7.8 (SD = 6.6) for the group “55–64 years” and 6.7 (SD
= 5.6) for the group “65 years old and above” (p < 0.0001).
Quality of life was also linked to the localization of the psoria-
sis. CONCLUSIONS: Quality of life assessed through the DLQI
shows an important impairment in the study population with a
mean score of 8.3. In comparison with other studies using the
DLQI; a score of 8.9 was found for severe psoriasis, 12.5 for
atopic dermatitis and 4.3 for acne.
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